ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
Dow Jones
39,869.38
-0.10%
US Dollar vs MXN
16.69305
0.07%
Brent Oil
83.215
0.01%
Bitcoin
66,432.27
1.83%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Y mAbs Therapeutics Inc (YMAB)

  7. Y mAbs Therapeutics Inc (YMAB) Noticias

YMAB

Y mAbs Therapeutics (YMAB)

Y mAbs Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:YMAB
FechaHoraFuenteTítuloSímboloCompañía
07/05/202415:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:YMABY mAbs Therapeutics Inc
07/05/202415:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
07/05/202415:05GlobeNewswire Inc.Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
26/04/202406:05GlobeNewswire Inc.Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024NASDAQ:YMABY mAbs Therapeutics Inc
25/04/202415:05GlobeNewswire Inc.Y-mAbs to Present at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
14/03/202408:05GlobeNewswire Inc.Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerNASDAQ:YMABY mAbs Therapeutics Inc
07/03/202416:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
06/03/202415:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
04/03/202406:30GlobeNewswire Inc.Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of DirectorsNASDAQ:YMABY mAbs Therapeutics Inc
29/02/202416:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:YMABY mAbs Therapeutics Inc
29/02/202415:05GlobeNewswire Inc.Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
16/02/202406:30GlobeNewswire Inc.Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024NASDAQ:YMABY mAbs Therapeutics Inc
06/02/202414:59Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:YMABY mAbs Therapeutics Inc
02/01/202415:05GlobeNewswire Inc.Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:YMABY mAbs Therapeutics Inc
13/12/202315:05GlobeNewswire Inc.Y-mAbs Therapeutics Added to the NASDAQ Biotechnology IndexNASDAQ:YMABY mAbs Therapeutics Inc
13/11/202315:05GlobeNewswire Inc.Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
08/11/202316:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
31/10/202306:05GlobeNewswire Inc.Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023NASDAQ:YMABY mAbs Therapeutics Inc
18/10/202315:05GlobeNewswire Inc.Y-mAbs Names Michael Rossi as President and Chief Executive Officer and DirectorNASDAQ:YMABY mAbs Therapeutics Inc
17/10/202317:01Dow Jones NewsY-mAbs Therapeutics New Drug Application Gets FDA ClearanceNASDAQ:YMABY mAbs Therapeutics Inc
17/10/202315:05GlobeNewswire Inc.Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADANASDAQ:YMABY mAbs Therapeutics Inc
16/10/202315:05GlobeNewswire Inc.Y-mAbs Announces Publication in CancersNASDAQ:YMABY mAbs Therapeutics Inc
21/09/202315:05GlobeNewswire Inc.Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric OncologyNASDAQ:YMABY mAbs Therapeutics Inc
06/09/202315:05GlobeNewswire Inc.Y-mAbs to Participate at Upcoming Investor Conferences in SeptemberNASDAQ:YMABY mAbs Therapeutics Inc
10/08/202315:05GlobeNewswire Inc.Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
02/08/202315:05GlobeNewswire Inc.Y-mAbs to Participate at Upcoming Investor ConferencesNASDAQ:YMABY mAbs Therapeutics Inc
01/08/202315:05GlobeNewswire Inc.Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023NASDAQ:YMABY mAbs Therapeutics Inc
09/06/202317:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:YMABY mAbs Therapeutics Inc
09/06/202316:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:YMABY mAbs Therapeutics Inc
26/05/202308:00GlobeNewswire Inc.Y-mAbs Announces Presentation of GD2-SADA Study at ASCONASDAQ:YMABY mAbs Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:YMAB

Su Consulta Reciente

AMEX
CLSE
Convergence Long Short E...
NASDAQ
AAWMSXX
Jpmorgan Chase Financial...
COIN
PEXUSD
ASX
TLSKOH
COIN
YFDAIUST
YfDAI.finance
USOTC
KYDNF
Kyoden (CE)
COIN
GOLDRETH
BOV
TFCO4F
Track & Field PN
BIT
XYLD
Xtrackers ESG USD Corpor...
LSE
WIX
Wickes
NYSE
BSMX
Banco Santander Mexico S...
NYSE
PFB
Pff Bancorp
NASDAQ
AAYIEXX
Jpmorgan Chase Financial...
LSE
5HED
Ossiam Etf Esgd
NASDAQ
HOLX
Hologic
CSE
PHI
Philippine Metals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados